CA2943711A1 - Novel methods for inducing an immune response - Google Patents
Novel methods for inducing an immune response Download PDFInfo
- Publication number
- CA2943711A1 CA2943711A1 CA2943711A CA2943711A CA2943711A1 CA 2943711 A1 CA2943711 A1 CA 2943711A1 CA 2943711 A CA2943711 A CA 2943711A CA 2943711 A CA2943711 A CA 2943711A CA 2943711 A1 CA2943711 A1 CA 2943711A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- months
- use according
- administration
- adjuvant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1405921.6 | 2014-04-02 | ||
GBGB1405921.6A GB201405921D0 (en) | 2014-04-02 | 2014-04-02 | Novel methods for inducing an immune response |
PCT/EP2015/057423 WO2015150567A1 (en) | 2014-04-02 | 2015-04-02 | Novel methods for inducing an immune response |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2943711A1 true CA2943711A1 (en) | 2015-10-08 |
Family
ID=50737873
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2943711A Abandoned CA2943711A1 (en) | 2014-04-02 | 2015-04-02 | Novel methods for inducing an immune response |
CA2943007A Active CA2943007C (en) | 2014-04-02 | 2015-04-02 | Novel methods for inducing an immune response |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2943007A Active CA2943007C (en) | 2014-04-02 | 2015-04-02 | Novel methods for inducing an immune response |
Country Status (18)
Country | Link |
---|---|
US (3) | US10624961B2 (ru) |
EP (2) | EP3125929B8 (ru) |
JP (2) | JP6655549B2 (ru) |
KR (2) | KR20230075525A (ru) |
CN (2) | CN106456738B (ru) |
AR (1) | AR099960A1 (ru) |
AU (1) | AU2015239025B2 (ru) |
BE (1) | BE1022355B1 (ru) |
BR (2) | BR112016022787A2 (ru) |
CA (2) | CA2943711A1 (ru) |
EA (1) | EA037405B1 (ru) |
ES (2) | ES2853773T3 (ru) |
GB (1) | GB201405921D0 (ru) |
IL (1) | IL247493B (ru) |
MX (3) | MX2016012932A (ru) |
SG (1) | SG11201607086QA (ru) |
WO (2) | WO2015150568A1 (ru) |
ZA (1) | ZA201605955B (ru) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201405921D0 (en) * | 2014-04-02 | 2014-05-14 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
GB201621686D0 (en) * | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
IE87414B1 (en) | 2017-05-30 | 2023-07-19 | Glaxosmithkline Biologicals Sa | Novel methods for manufacturing an adjuvant |
BR112020010790A2 (pt) | 2017-12-01 | 2020-11-10 | Glaxosmithkline Biologicals S.A. | purificação da saponina |
JP2022535091A (ja) | 2019-06-05 | 2022-08-04 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | サポニン精製 |
CN113125756B (zh) * | 2020-07-15 | 2022-10-25 | 南京岚煜生物科技有限公司 | 抗体标准品赋值和抗原中和当量确定的方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US152200A (en) * | 1874-06-16 | Improvement in garters | ||
US1002607A (en) * | 1905-08-28 | 1911-09-05 | John Willard Taylor | Paper pulley. |
UA56132C2 (ru) * | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиция вакцины (варианты), способ стабилизации qs21 по отношению к гидролизу (варианты), способ приготовления вакцины |
US8232255B2 (en) | 2002-10-23 | 2012-07-31 | Glaxosmithkline Biologicals S.A. | Methods for vaccinating against malaria |
AU2005293572B2 (en) | 2004-10-14 | 2011-08-04 | Crucell Holland B.V. | Malaria prime/boost vaccines |
CN106390108B (zh) * | 2005-04-29 | 2020-09-08 | 葛兰素史密丝克莱恩生物有限公司 | 用于预防或治疗结核分枝杆菌感染的新方法 |
TWI457133B (zh) * | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
WO2008140478A2 (en) * | 2006-11-01 | 2008-11-20 | Immport Therapeutics, Inc. | Compositions and methods for immunodominant antigens |
CN103550764A (zh) * | 2007-03-02 | 2014-02-05 | 葛兰素史密丝克莱恩生物有限公司 | 疫苗组合物及其在刺激免疫反应中的用途 |
AR066405A1 (es) * | 2007-04-20 | 2009-08-19 | Glaxosmithkline Biolog Sa | Vacuna |
KR20160013262A (ko) * | 2008-07-25 | 2016-02-03 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 신규한 조성물 및 방법 |
UA107330C2 (ru) * | 2008-07-25 | 2014-12-25 | Глаксосмітклайн Байолоджікалз С.А. | Туберкулезный белок rv3616c и его применение |
JP5981138B2 (ja) * | 2008-07-25 | 2016-08-31 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 結核Rv2386cタンパク質、組成物およびその使用 |
BR112012018669A2 (pt) * | 2010-01-27 | 2017-09-05 | Glaxosmithkline Biologicals Sa | Proteína rv3616c modificada, uso de uma proteína rv3616c modificada, polinucleotídeo, uso de um polinucleotídeo, composição farmacêutica, composição imunogênica, proteína de fusão, e, polipeptídeo. |
CN103260642B (zh) * | 2010-12-14 | 2018-03-16 | 葛兰素史密丝克莱恩生物有限公司 | 分枝杆菌抗原组合物 |
WO2015126930A2 (en) * | 2014-02-18 | 2015-08-27 | Stc.Unm | Booster drug therapy for mycobacterium infections |
GB201405921D0 (en) * | 2014-04-02 | 2014-05-14 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
CN106232138A (zh) * | 2014-04-24 | 2016-12-14 | 国家血清研究所 | 新型结核分枝杆菌疫苗 |
GB201513176D0 (en) * | 2015-07-27 | 2015-09-09 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
-
2014
- 2014-04-02 GB GBGB1405921.6A patent/GB201405921D0/en not_active Ceased
-
2015
- 2015-04-02 BE BE2015/5209A patent/BE1022355B1/fr not_active IP Right Cessation
- 2015-04-02 US US15/300,338 patent/US10624961B2/en active Active
- 2015-04-02 CN CN201580016665.4A patent/CN106456738B/zh active Active
- 2015-04-02 EA EA201691638A patent/EA037405B1/ru not_active IP Right Cessation
- 2015-04-02 CA CA2943711A patent/CA2943711A1/en not_active Abandoned
- 2015-04-02 KR KR1020237017095A patent/KR20230075525A/ko not_active Application Discontinuation
- 2015-04-02 IL IL247493A patent/IL247493B/en unknown
- 2015-04-02 ES ES15713531T patent/ES2853773T3/es active Active
- 2015-04-02 JP JP2016560336A patent/JP6655549B2/ja active Active
- 2015-04-02 WO PCT/EP2015/057424 patent/WO2015150568A1/en active Application Filing
- 2015-04-02 JP JP2016559965A patent/JP6645982B2/ja active Active
- 2015-04-02 CA CA2943007A patent/CA2943007C/en active Active
- 2015-04-02 AU AU2015239025A patent/AU2015239025B2/en active Active
- 2015-04-02 BR BR112016022787-5A patent/BR112016022787A2/pt not_active Application Discontinuation
- 2015-04-02 WO PCT/EP2015/057423 patent/WO2015150567A1/en active Application Filing
- 2015-04-02 BR BR112016022463A patent/BR112016022463A2/pt not_active Application Discontinuation
- 2015-04-02 CN CN201580030331.2A patent/CN106456739A/zh active Pending
- 2015-04-02 ES ES15713532T patent/ES2961840T3/es active Active
- 2015-04-02 EP EP15713532.8A patent/EP3125929B8/en active Active
- 2015-04-02 MX MX2016012932A patent/MX2016012932A/es unknown
- 2015-04-02 US US15/300,852 patent/US10688168B2/en active Active
- 2015-04-02 EP EP15713531.0A patent/EP3125930B1/en active Active
- 2015-04-02 MX MX2016012982A patent/MX2016012982A/es unknown
- 2015-04-02 KR KR1020167029523A patent/KR20160132115A/ko not_active IP Right Cessation
- 2015-04-02 SG SG11201607086QA patent/SG11201607086QA/en unknown
- 2015-04-06 AR ARP150101025A patent/AR099960A1/es unknown
-
2016
- 2016-08-26 ZA ZA2016/05955A patent/ZA201605955B/en unknown
- 2016-09-30 MX MX2022013912A patent/MX2022013912A/es unknown
-
2020
- 2020-03-11 US US16/815,635 patent/US11951161B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10441648B2 (en) | Mycobacterium antigenic composition | |
US10688168B2 (en) | Methods for inducing an immune response |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20200401 |
|
FZDE | Discontinued |
Effective date: 20220719 |
|
FZDE | Discontinued |
Effective date: 20220719 |